A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)

Trial Profile

A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)

Active, no longer recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 19 Jul 2018

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms TOPAZ
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 19 Jun 2018 Results presenting efficacy/safety outcomes over 7 years (2 years core study plus 4 years extension and TOPAZ Y1) in alemtuzumab-treated patients from CARE-MS presented at the 4th Congress of the European Academy of Neurology
    • 19 Jun 2018 Results presenting MRI lesion/BVL outcomes over 7 y (2 y core study plus 4 y extension, and TOPAZ Y1) in alemtuzumab-treated CARE-MS I patients presented at the 4th Congress of the European Academy of Neurology
    • 03 May 2018 Planned number of patients changed from 812 to 1248.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top